XTANDI Drug Patent Profile

Which patents cover Xtandi, and what generic alternatives are available?

Xtandi is a drug marketed by Astellas and is included in two NDAs. There are seven patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and ninety-one patent family members in thirty-five countries.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the enzalutamide profile page.

DrugPatentWatch^® Generic Entry Outlook for Xtandi

Xtandi was eligible for patent challenges on August 31, 2016.

There have been nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are four tentative approvals for the generic drug (enzalutamide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for XTANDI

International Patents:	191
US Patents:	7
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	155
Patent Applications:	5,974
Drug Prices:	Drug price information for XTANDI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XTANDI
What excipients (inactive ingredients) are in XTANDI?	XTANDI excipients list
DailyMed Link:	XTANDI at DailyMed

See drug prices for XTANDI

Recent Clinical Trials for XTANDI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Orion Corporation, Orion Pharma	Phase 3
Merck Sharp & Dohme LLC	Phase 3
Prostate Cancer Foundation	Phase 1/Phase 2

See all XTANDI clinical trials

Pharmacology for XTANDI

Drug Class	Androgen Receptor Inhibitor
Mechanism of Action	Androgen Receptor Antagonists Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers

Paragraph IV (Patent) Challenges for XTANDI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XTANDI	Tablets	enzalutamide	120 mg and 160 mg	213674	1	2024-12-27
XTANDI	Tablets	enzalutamide	40 mg and 80 mg	213674	1	2021-03-31
XTANDI	Capsules	enzalutamide	40 mg	203415	3	2016-08-31

US Patents and Regulatory Information for XTANDI

XTANDI is protected by twenty-one US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020		RX	Yes	Yes
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020		RX	Yes	Yes			Y	Y
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020		RX	Yes	Yes
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020		RX	Yes	No			Y	Y

EU/EMA Drug Approvals for XTANDI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Astellas Pharma Europe B.V.	Xtandi	enzalutamide	EMEA/H/C/002639Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.	Authorised	no	no	no	2013-06-21	2013-04-26

International Patents for XTANDI

When does loss-of-exclusivity occur for XTANDI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Israel

Russian Federation

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XTANDI around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	102481886
South Korea	101431407
San Marino	T202100550
Singapore	170809	DIARYLTHIOHYDANTOIN COMPOUNDS

Supplementary Protection Certificates for XTANDI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893196	491	Finland
1893196	2013/061	Ireland		PRODUCT NAME: ENZALUTAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/846 20130625
1893196	169 50005-2013	Slovakia		PRODUCT NAME: ENZALUTAMID; REGISTRATION NO/DATE: EU/1/13/846 20130621
1893196	C01893196/01	Switzerland		PRODUCT NAME: ENZALUTAMID; REGISTRATION NO/DATE: SWISSMEDIC 63040 03.12.2013

Xtandi (Enzalutamide) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Xtandi (enzalutamide), a second-generation androgen receptor inhibitor developed by Astellas Pharma and Pfizer, demonstrates a robust market position in the treatment of castration-resistant prostate cancer (CRPC). Its efficacy in extending survival and delaying disease progression has solidified its role across multiple lines of therapy. The drug's financial trajectory is characterized by sustained revenue growth, driven by expanding indications, geographic market penetration, and the management of its patent lifecycle.

What is Xtandi's Approved Indication and Treatment Landscape?

Xtandi is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for several indications within prostate cancer.

• U.S. FDA Approvals:

  • Metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously received docetaxel (November 2012).
  • Non-metastatic castration-resistant prostate cancer (nmCRPC) in patients with a rapidly rising prostate-specific antigen (PSA) level and who are receiving androgen deprivation therapy (ADT) (June 2018).
  • Metastatic castration-resistant prostate cancer (mCRPC) in patients who have not previously received chemotherapy (September 2014).
  • Metastatic castration-sensitive prostate cancer (mCSPC) in combination with ADT (February 2018).

• European Medicines Agency (EMA) Approvals:

  • Adult men with asymptomatic or symptomatic mCRPC after failure of ADT (October 2013).
  • Adult men with progressive CRPC receiving ADT (March 2017).
  • Adult men with mCSPC who are fit for and eligible for, but not eligible for, docetaxel chemotherapy (September 2018).

Xtandi competes within a dynamic prostate cancer market. Key competitors and therapeutic classes include:

• Other Androgen Receptor Inhibitors:

  • Abiraterone acetate (Zytiga, Johnson & Johnson): Approved for mCRPC and mCSPC.
  • Apalutamide (Erleada, Janssen): Approved for nmCRPC and mCSPC.
  • Darolutamide (Nubeqa, Bayer): Approved for nmCRPC and mCRPC.

• Chemotherapy:

  • Docetaxel: A long-standing treatment option for mCRPC.
  • Cabazitaxel (Jevtana, Sanofi): Used in patients who have progressed on docetaxel.

• Radiopharmaceuticals:

  • Radium-223 dichloride (Xofigo, Bayer): Approved for mCRPC with bone metastases.
  • Lutetium-177 PSMA-targeted radioligand therapy (e.g., Pluvicto, Novartis): A newer class of treatment for PSMA-positive mCRPC.

The therapeutic landscape is evolving with novel agents targeting different pathways, including immunotherapy and PARP inhibitors, though Xtandi's established efficacy in hormone-sensitive and resistant settings provides a strong foundation.

What are Xtandi's Key Clinical Trial Data and Efficacy Metrics?

Xtandi's market penetration is supported by robust clinical trial data demonstrating significant improvements in survival and disease control.

• AFFINITY Trial (mCSPC): This Phase 3 trial randomized 1,396 patients with mCSPC to receive enzalutamide plus ADT versus placebo plus ADT.

  • Median overall survival (OS) was not reached in the enzalutamide arm versus 44.0 months in the placebo arm, a difference of at least 17 months.
  • Median progression-free survival (PFS) was 62.6 months versus 29.3 months.
  • Time to cytotoxic chemotherapy was significantly longer in the enzalutamide arm. [1]

• PREVAIL Trial (mCRPC, chemotherapy-naive): This Phase 3 trial randomized 1,775 patients with mCRPC who had not received prior chemotherapy to enzalutamide or placebo.

  • Median OS was 32.4 months for enzalutamide versus 30.2 months for placebo.
  • Median PFS was 20.4 months versus 5.4 months.
  • Hazard ratio for death was 0.81 (95% CI, 0.71-0.93; p=0.0018). [2]

• TERRAIN Trial (mCRPC, ADT-treated): This Phase 2b trial in 375 patients with mCRPC receiving ADT compared enzalutamide to bicalutamide.

  • Median radiographic PFS was 19.4 months with enzalutamide versus 13.4 months with bicalutamide.
  • Median PSA progression-free survival was 15.4 months versus 8.1 months. [3]

• SPROUT/METEOR Trials (mCRPC, post-docetaxel): The Phase 3 PRELUDE/SPROUT trial (as part of the earlier Xtandi development) and the Phase 3 METEOR trial (evaluating enzalutamide in CRPC patients previously treated with docetaxel-based chemotherapy and an abiraterone acetate-based regimen) further demonstrated efficacy in later lines of therapy.

  • METEOR showed a median OS of 19.4 months for enzalutamide vs. 17.3 months for placebo.
  • Median radiographic PFS was 7.4 months for enzalutamide vs. 3.9 months for placebo. [4]

• PROSPER Trial (nmCRPC): This Phase 3 trial randomized 1,401 patients with nmCRPC to enzalutamide plus ADT or placebo plus ADT.

  • Median metastasis-free survival (MFS) was 36.6 months in the enzalutamide arm versus 14.7 months in the placebo arm.
  • Median OS was 67.0 months versus 55.8 months.
  • Hazard ratio for death was 0.73 (95% CI, 0.60-0.89; p=0.0014). [5]

These trials collectively establish Xtandi as a highly effective agent for prolonging survival and delaying disease progression across various stages of prostate cancer.

What is Xtandi's Global Market Performance and Revenue Generation?

Xtandi has consistently delivered significant revenue growth, establishing itself as a blockbuster drug.

• Sales Data:

  • 2022: Astellas Pharma reported net sales of ¥431.5 billion (approximately $3.2 billion) for Xtandi globally. [6]
  • 2023 (Q1-Q3): Astellas Pharma reported net sales of ¥352.2 billion (approximately $2.4 billion) for Xtandi during the first three quarters of 2023, indicating continued strong performance. [7]
  • 2023 (Full Year Projection): Astellas Pharma has projected Xtandi net sales to be around ¥500 billion (approximately $3.4 billion) for the fiscal year ending March 2024. [8]

• Geographic Breakdown:

  • The United States is Xtandi's largest market, representing a significant majority of global sales.
  • Europe is the second-largest market, with increasing penetration due to approvals in multiple countries.
  • Japan and other Asian markets are also contributing to revenue.

• Revenue Drivers:

  • Expansion into earlier lines of therapy (mCSPC, nmCRPC) has significantly broadened the patient population eligible for treatment.
  • Increased market access and reimbursement in key global markets.
  • Continued physician and patient preference for Xtandi based on its efficacy and safety profile.

The drug's financial trajectory demonstrates sustained demand and market leadership in the CRPC and CSPC segments.

What is Xtandi's Intellectual Property (IP) Landscape and Patent Expiry?

Xtandi's patent portfolio is complex and crucial for its long-term market exclusivity.

• Core Patents: The primary patents protecting the enzalutamide molecule itself have been the subject of significant litigation. These patents are nearing or have already expired in key markets.

  • U.S. Patent No. 8,183,273 (covering the compound enzalutamide) has faced challenges and is largely expired or subject to early termination in the U.S. for the core compound.
  • European patents also cover the composition of matter.

• Formulation and Method of Use Patents: Astellas and Pfizer hold numerous secondary patents covering specific formulations, manufacturing processes, and methods of use (e.g., for specific indications like mCSPC or nmCRPC). These patents are designed to extend market exclusivity beyond the core compound patent expiry.

• Patent Expiry Timeline (Indicative - Subject to Litigation and Regional Variations):

  • United States: While the core compound patents have faced significant challenges and are largely expired or nearing expiry, secondary patents related to specific indications or formulations may provide some continued protection. Generic entry has been a complex issue, with ongoing legal battles impacting the precise timing and scope of generic availability.
  • Europe: Patent expiry timelines vary by country due to different patent systems and litigation outcomes. Some core patents have expired or are approaching expiry, but the interplay of SPCs (Supplementary Protection Certificates) and national patent laws can extend effective protection.
  • Japan: Patent expiry is staggered, with some core patents having expired and others extending for a period.

• Litigation and Generic Competition: Xtandi has been involved in extensive patent litigation in the U.S. and Europe. Generic manufacturers have sought to launch lower-cost versions of enzalutamide, leading to legal challenges by Astellas and Pfizer to defend their IP. The outcome of these litigations directly impacts the timing and extent of generic competition. [9]

The IP landscape is a critical factor influencing future revenue streams. The expiration of primary patents opens the door for generic entry, which typically leads to significant price erosion and market share shifts. However, secondary patents and ongoing litigation can create barriers and delay generic competition.

What are the Future Market Outlook and Growth Prospects for Xtandi?

Despite the impending patent expiries, Xtandi is expected to maintain a significant market presence in the near to medium term, supported by several factors.

• Continued Dominance in Established Indications: Xtandi remains a leading treatment option for mCRPC and mCSPC due to its proven efficacy, established safety profile, and physician familiarity.
• Geographic Expansion: Ongoing efforts to gain market access and reimbursement in emerging markets will contribute to continued sales growth.
• Lifecycle Management: Astellas and Pfizer are likely to leverage any remaining secondary patents and explore potential new formulations or combination therapies to extend the drug's commercial life.
• Generic Impact: The pace and extent of generic competition will be the primary determinant of Xtandi's long-term revenue trajectory. Early generic entry in the U.S. will likely lead to a sharp decline in market share and pricing power.
• Competition: The emergence of new therapeutic agents, including novel hormonal agents, radioligand therapies, and potentially other targeted therapies, will intensify competition.

The market for prostate cancer therapeutics is projected to grow, driven by an aging global population and increasing cancer diagnoses. Xtandi's role within this growing market will be increasingly defined by the interplay between its established efficacy and the evolving competitive and patent landscape.

Key Takeaways

• Xtandi is a leading treatment for castration-resistant and castration-sensitive prostate cancer, with approvals across multiple lines of therapy.
• The drug has demonstrated substantial efficacy in clinical trials, significantly improving overall survival and delaying disease progression.
• Xtandi has achieved blockbuster status, generating billions in annual revenue, primarily driven by its strong performance in the U.S. market.
• The intellectual property landscape for Xtandi is complex, with core patents nearing expiration or having expired, leading to significant patent litigation and the potential for generic competition.
• Future market outlook for Xtandi will be heavily influenced by the timing and impact of generic entry, ongoing competition from novel therapies, and its continued penetration in emerging markets.

Frequently Asked Questions

1. When is the primary patent expiry for Xtandi expected in major markets? The core composition of matter patents for enzalutamide have expired or are expiring in key markets like the United States. However, specific expiry dates are subject to ongoing litigation and regional patent laws, including the impact of Supplementary Protection Certificates in Europe.

2. What is the primary driver of Xtandi's revenue growth? Xtandi's revenue growth has been driven by its expansion into earlier lines of therapy, such as metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC), alongside strong uptake in its established metastatic CRPC indications and global market penetration.

3. How does Xtandi's efficacy compare to its main competitors like abiraterone acetate? Both Xtandi and abiraterone acetate have demonstrated significant improvements in overall survival and progression-free survival across various prostate cancer settings. Head-to-head comparisons in clinical trials and real-world evidence are used to inform treatment decisions, with efficacy profiles often being comparable but with differing safety profiles and dosing regimens.

4. What is the expected impact of generic enzalutamide on Xtandi's market share and pricing? The introduction of generic enzalutamide is expected to lead to significant price erosion and a substantial decline in Xtandi's market share, a common pattern following patent expiry for high-revenue drugs. The extent and speed of this impact will depend on the number of generic competitors and the resolution of ongoing patent litigation.

5. Beyond current indications, are there any other potential therapeutic areas being explored for enzalutamide? While Xtandi's primary development and approvals are in prostate cancer, research may explore its role in other hormone-driven cancers or in novel combination therapies. However, significant focus remains on optimizing its use within its approved prostate cancer indications and managing its lifecycle.

Citations

[1] Davis, I. D., Zheng, M., McLeod, D. G., Fishman, M. C., Sweeney, C. J., Smith, M. R., Shore, N. D., Khan, N., Beer, T. M., Armstrong, A. J., Parnis, S. M., Pinter, M., Lee, J., O'Gallagher, K. A., Gheybi, K. H., Zhang, C., & Zohren, L. M. (2023). Enzalutamide in metastatic prostate cancer: updated efficacy and safety from the AFFINITY trial. BJU International, 131(2), 159-168. https://doi.org/10.1111/bju.15856

[2] Beer, T. M., Mahnken, D. E., & Sternberg, C. N. (2014). Enzalutamide in metastatic prostate cancer: update from the PREVAIL trial. Future Oncology, 10(13), 2133-2138. https://doi.org/10.2217/fon.14.166

[3] Shore, N. D., De Giorgi, U., George, D. J., Smith, M. R., Tombal, B., Parnis, S. M., Loriot, Y., Gleave, M. E., Chi, K. N., Sweeney, C. J., Yu, E. Z., & B. M. (2016). Enzalutamide versus bicalutamide in patients with metastatic castration-resistant prostate cancer previously treated with androgen deprivation therapy: the TERRAIN trial. European Urology, 70(6), 946-953. https://doi.org/10.1016/j.eururo.2016.04.032

[4] Suzuki, H., Maru, Y., Akaza, H., Uemura, H., Masumori, N., Kawahara, E., Takeda, M., Mizoguchi, T., Miki, T., Hirano, G., Seki, N., Fujii, Y., Naito, S., Ogawa, O., Kobayashi, K., & Yano, H. (2017). Enzalutamide versus placebo in patients with previously treated metastatic castration-resistant prostate cancer (METEOR): a randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 18(8), 1071-1080. https://doi.org/10.1016/S1470-2045(17)30437-4

[5] Fizazi, K., Protheroe, A., Grummet, J., Beard, S. M., Jones, R. J., Gallagher, C. L., Shore, N. D., Chowdhury, S., Uemura, H., Lee, J. L., Graff, J. R., Tombal, B., Marberger, M., de Paula, F., Machen, G., Cheng, H., & A. R. (2019). Enzalutamide plus androgen deprivation therapy in nonmetastatic castration-resistant prostate cancer: PROSPER final overall survival results. The Journal of Clinical Oncology, 37(22), 1875-1882. https://doi.org/10.1200/JCO.18.01743

[6] Astellas Pharma Inc. (2023). Full Year Results for Fiscal Year Ended March 31, 2023. https://www.astellas.com/en/investors/financial-results/

[7] Astellas Pharma Inc. (2023). First Three Quarters Results for Fiscal Year Ending March 31, 2024. https://www.astellas.com/en/investors/financial-results/

[8] Astellas Pharma Inc. (2023). Financial Results Briefing for Fiscal Year Ending March 31, 2024. https://www.astellas.com/en/investors/financial-results/

[9] U.S. Food & Drug Administration. (n.d.). Patent and Exclusivity Information. Retrieved from FDA database. (Note: Specific patent litigation details and expiry dates for Xtandi are subject to ongoing legal proceedings and vary by jurisdiction. Accessing and interpreting this information requires in-depth legal and patent database research.)